Loading clinical trials...
Loading clinical trials...
A Prospective, Single-arm Phase 2 Study Evaluating the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection Combined with PD-1 Blockade in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma
Conditions
Interventions
Mitoxantrone hydrochloride liposome injection
PD-1 Inhibitors
Locations
1
China
The Fifth Affiliated Hospital, Sun Yat-sen University
Zhuhai, Guangdong, China
Start Date
July 20, 2024
Primary Completion Date
October 31, 2025
Completion Date
September 30, 2027
Last Updated
January 13, 2025
NCT06976190
NCT07258979
NCT06241599
Lead Sponsor
Ming-Yuan Chen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions